Knight Therapeutics Company Profile (TSE:GUD)

About Knight Therapeutics

Knight Therapeutics logoKnight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: TSE
  • Symbol: GUD
  • CUSIP:
Key Metrics:
  • Previous Close: $10.83
  • 50 Day Moving Average: $10.45
  • 200 Day Moving Average: $9.65
  • 52-Week Range: C$7.20 - C$11.03
  • Trailing P/E Ratio: 75.28
  • P/E Growth: 2741.00
  • Market Cap: $1.42B
  • Outstanding Shares: 132,704,000
Additional Links:

Analyst Ratings

Consensus Ratings for Knight Therapeutics (TSE:GUD) (?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: C$10.51

Analysts' Ratings History for Knight Therapeutics (TSE:GUD)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2017TD SecuritiesReiterated RatingBuyC$12.50View Rating Details
1/13/2017CIBCLower Price TargetC$13.00 -> C$9.80View Rating Details
1/4/2017MackieDowngradeBuy -> HoldC$12.00 -> C$10.75View Rating Details
12/23/2016ScotiabankBoost Price TargetOutperformC$10.00 -> C$10.50View Rating Details
11/10/2016Bloom BurtonReiterated RatingAccumulateView Rating Details
3/10/2016Paradigm CapitalSet Price TargetBuyC$9.00View Rating Details
3/2/2016Dundee SecuritiesReiterated RatingNeutralView Rating Details
5/14/2015LaurentianLower Price TargetHoldC$9.50 -> C$8.50View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Knight Therapeutics (TSE:GUD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/15/2014($0.01)$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Knight Therapeutics (TSE:GUD)
Current Year EPS Consensus Estimate: $0.13 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.06$0.06$0.06
Q2 20161$0.06$0.06$0.06
Q3 20161$0.04$0.04$0.04
Q4 20161$0.03$0.03$0.03
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Knight Therapeutics (TSE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Knight Therapeutics (TSE:GUD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2015Robert Nathaniel LandeDirectorSell57,000C$8.85C$504,267.60
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Knight Therapeutics (TSE:GUD)
DateHeadline
finance.yahoo.com logoKnight Therapeutics Inc. Announces Board Change (TSE:GUD)
finance.yahoo.com - February 23 at 5:33 PM
News IconInvestor Scope: Taking a Closer Look at Shares of Knight Therapeutics Inc. (TSX:GUD) - Piedmont Register (TSE:GUD)
piedmontregister.com - February 23 at 3:47 AM
streetinsider.com logoAlimera Sciences (ALIM), Knight Therapeutics Announce Filing of New Drug Submission for Iluvien in Canada (TSE:GUD)
www.streetinsider.com - February 22 at 5:45 PM
News IconKnight Therapeutics Inc GUD Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (TSE:GUD)
www.bioportfolio.com - February 18 at 12:19 PM
News IconProtalix Bio Therapeutics, Inc. (NYSE:PLX) Market Confidence Back After Knight Therapeutics Invests - StockNewsUnion (TSE:GUD)
stocknewsunion.com - February 13 at 6:29 PM
News IconDirectional Index Update on Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - February 6 at 5:37 PM
News IconFocusing on the Numbers for Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - February 3 at 6:05 PM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : GUD-CA : February 1, 2017 (TSE:GUD)
www.capitalcube.com - February 1 at 6:18 PM
seekingalpha.com logoProtalix BioTherapeutics Is Making Significant Progress And The Market Is Beginning To Notice (TSE:GUD)
seekingalpha.com - January 31 at 6:13 PM
News IconTrading Watch: FCF and Piotroski Score Check for Knight Therapeutics Inc. (TSX:GUD) - Gilbert Daily (TSE:GUD)
gilbertdaily.com - January 30 at 6:17 PM
News IconSpot-check on CCI and RSI for Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 30 at 6:17 PM
News IconKnight Therapeutics Inc GUD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (TSE:GUD)
www.bioportfolio.com - January 28 at 10:43 PM
News IconRegulus Therapeutics (RGLS) Plunges on FDA Decision; Knight Therapeutics Eyeing Potential In Protalix ... - Galaxy Stocks (press release) (registration) (TSE:GUD)
galaxystocks.com - January 27 at 7:29 PM
News IconEquity Focus: Looking at Shares of Knight Therapeutics Inc. (TSX:GUD) - Gilbert Daily (TSE:GUD)
gilbertdaily.com - January 27 at 7:29 PM
News IconTrading Review: Technical Survey on Shares of Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 27 at 7:29 PM
nasdaq.com logoIMGN Marches Forward, FDA Nod For ZLTQ, Knight Lends Shine To ... - Nasdaq (TSE:GUD)
www.nasdaq.com - January 27 at 5:05 AM
News IconUpdate on Valuation Formula's For Knight Therapeutics Inc. (TSX:GUD) - Gilbert Daily (TSE:GUD)
gilbertdaily.com - January 27 at 5:05 AM
benzinga.com logoKnight Plants Small Seed Position In Protalix - Benzinga (TSE:GUD)
www.benzinga.com - January 27 at 5:05 AM
rttnews.com logoIMGN Marches Forward, FDA Nod For ZLTQ, Knight Lends Shine To PLX (TSE:GUD)
www.rttnews.com - January 27 at 12:04 AM
News IconTrading Scope: ADX and CCI Review for Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 26 at 7:02 PM
News IconChecking the Metrics on Shares of Knight Therapeutics Inc. (TSX:GUD) - Gilbert Daily (TSE:GUD)
gilbertdaily.com - January 25 at 6:58 PM
News IconIndicator Review on Shares of Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 25 at 6:58 PM
News IconStock Update: Focusing on Shares of Knight Therapeutics Inc. (TSX:GUD) - Gilbert Daily (TSE:GUD)
gilbertdaily.com - January 24 at 6:20 PM
News IconInvestor Focus on Technical Levels for Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 24 at 6:20 PM
capitalcube.com logoKnight Therapeutics, Inc. – Value Analysis (TORONTO:GUD) : January 23, 2017 (TSE:GUD)
www.capitalcube.com - January 23 at 5:57 PM
News IconTrading Spotlight: Zooming in on Shares of Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 23 at 11:13 AM
News IconInvestor Sphere: Keeping an Eye on Levels for Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 20 at 6:53 PM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : January 20, 2017 (TSE:GUD)
www.capitalcube.com - January 20 at 6:53 PM
News IconTechnical Level Spotcheck on Shares of Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 19 at 7:21 PM
News IconTechnical Investor Update on Shares of Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 18 at 6:01 PM
News IconQuick Review on Trend Indicator Levels: Knight Therapeutics Inc (GUD.TO) - Rives Journal (TSE:GUD)
rivesjournal.com - January 17 at 8:36 PM
4-traders.com logoKnight Therapeutics : Disposes of Shares of Pediapharm Inc. (TSE:GUD)
www.4-traders.com - January 14 at 4:48 AM
News IconKnight Therapeutics Inc. GUD Medical Equipment Deals and Alliances Profile Prices from USD $250 (TSE:GUD)
www.bioportfolio.com - January 13 at 4:03 AM
marketwatch.com logoSynergy CHC Corp creates deeper Partnership with Knight Therapeutics - MarketWatch (TSE:GUD)
www.marketwatch.com - January 4 at 6:36 PM
finance.yahoo.com logoSynergy CHC Corp creates deeper Partnership with Knight Therapeutics (TSE:GUD)
finance.yahoo.com - January 4 at 6:36 PM
News IconKnight Creates Many GUD Synergies with its Partner - Satellite PR News (press release) (TSE:GUD)
satprnews.com - December 29 at 3:36 AM
einnews.com logoThe Latest: Obama spends 4 hours playing golf with friends (TSE:GUD)
brazilbusiness.einnews.com - December 28 at 10:34 PM
marketwatch.com logoKnight Creates Many GUD Synergies with its Partner - MarketWatch (TSE:GUD)
www.marketwatch.com - December 28 at 5:32 PM
finance.yahoo.com logoKnight Creates Many GUD Synergies with its Partner (TSE:GUD)
finance.yahoo.com - December 28 at 5:32 PM
marketexclusive.com logoAnalyst Activity – Scotiabank Raises Its Price Target On Knight Therapeutics (TSE:GUD) to C$10.50 (TSE:GUD)
marketexclusive.com - December 24 at 5:20 PM
marketwired.com logoKnight Therapeutics Completes Previously Announced Bought Deal of Common Shares, Including Exercise of Over-Allotment Option, for $100 million (TSE:GUD)
www.marketwired.com - December 22 at 5:50 PM
News IconFollowing the Numbers on Shares of Knight Therapeutics Inc. (TSX:GUD) - Stock Newsweek (TSE:GUD)
stocknewsweek.com - December 22 at 4:31 AM
News IconVC Score In Focus for Knight Therapeutics Inc. (TSX:GUD) - Stock Newsweek (TSE:GUD)
stocknewsweek.com - December 21 at 6:28 PM
News IconInvestor Lookout: Technical Indicator Watch for Knight Therapeutics Inc (GUD.TO) - Wall Street Confidential (TSE:GUD)
wsconfidential.com - December 21 at 6:28 PM
marketwatch.com logoKnight Adds New Dimension to 3D Signatures Partnership - MarketWatch (TSE:GUD)
www.marketwatch.com - December 19 at 11:54 AM
News IconKeeping Tabs on Technicals for Knight Therapeutics Inc (GUD.TO) - Wall Street Confidential (TSE:GUD)
wsconfidential.com - December 19 at 11:54 AM
finance.yahoo.com logoKnight Adds New Dimension to 3D Signatures Partnership (TSE:GUD)
finance.yahoo.com - December 19 at 11:54 AM
News IconRSI Review on Shares of Knight Therapeutics Inc (GUD.TO) - Wall Street Confidential (TSE:GUD)
wsconfidential.com - December 17 at 5:51 PM
News IconTechnical Updates for Knight Therapeutics Inc (GUD.TO) - Wall Street Confidential (TSE:GUD)
wsconfidential.com - December 16 at 11:08 PM
marketwired.com logoKnight Therapeutics Announces Exclusive License Agreement with AstraZeneca for Movantik/Moventig® in Canada and Israel (TSE:GUD)
www.marketwired.com - December 16 at 4:11 AM

Social

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Tornton Stock Exchange (TSX) under the ticker symbol "GUD."

Where is Knight Therapeutics' stock going? Where will Knight Therapeutics' stock price be in 2017?

7 brokers have issued 12 month target prices for Knight Therapeutics' stock. Their predictions range from C$9.00 to C$12.50. On average, they anticipate Knight Therapeutics' stock price to reach C$10.51 in the next twelve months.

When will Knight Therapeutics announce their earnings?

Knight Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 9th 2016.

How do I buy Knight Therapeutics stock?

Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Knight Therapeutics stock cost?

One share of Knight Therapeutics stock can currently be purchased for approximately C$10.83.

Knight Therapeutics (TSE:GUD) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Knight Therapeutics (TSE:GUD)

Earnings History Chart

Earnings by Quarter for Knight Therapeutics (TSE:GUD)

Dividend History Chart

Dividend Payments by Quarter for Knight Therapeutics (TSE:GUD)

Last Updated on 2/24/2017 by MarketBeat.com Staff